TNFRSF17 and Miyoshi myopathy: Clinical trials, including KarMMa (for idecabtagene vicleucel, ide-cel) and CARTITUDE-1 (for ciltacabtagene autoleucel, cilta-cel), have shown high efficacy of BCMA-specific CAR T cells in patients with relapsing and refractory MM [104,105].